Abstract
AbstractTREM2 is a microglial receptor, sensitive to Phospholipids and Sphingomyelins, associated with neurodegeneration. Hypomorphic variants in theTREM2gene significantly increase the risk of developing AD.The main aim of this study was to characterize networks of lipids in post-mortem brain from AD and control donors, and to identify key lipids that are associated with AD and impacted by dysfunctional TREM2.We studied human post-mortem brain tissue from the hippocampus and the BA9 pre-association cortex from a total of 102 post-mortem brains. Specifically, brain tissue from the BA9 pre-association cortex was available for n=55 donors and brain tissue from the hippocampus was available for n=47 brain donors from three groups: AD donors with a non-synonymous risk DNA variant inTREM2(AD-TREM2var), AD donors with noTREM2-associated variant (AD-TREM2wt), and control donors. Mass Spectrometry was performed to obtain lipidomic signatures spanning 99 lipid species that included the following lipid classes: Ceramides, Sphingomyelins, Phosphatidic acids, Phopshatidyl-cholines, Phosphatidyl-ethalonamines, Phosphatidyl-glycerols, Phosphatidyl-inositols, Phosphatidyl-serines and Triglycerides. Weighted gene co-expression network analysis (WGCNA) was used to identify highly correlated lipid modules and ‘hub’ lipids. Linear mixed models and linear regression analyses, adjusted for age, biological sex, number of APOEε4 alleles and post-mortem delay were used to assess the association of modules and individual hub lipids with AD andTREM2status.Four lipid modules were found to be relatively well-preserved between the two brain regions, and three of these modules were altered in AD donors and/or in AD donors withTREM2genetic variants. Levels of the BA9 “turquoise” module (“blue” hippocampus module), enriched in Sphingolipids and Phospholipids, were elevated in AD brain donors and in AD TREM2 carriers. The key lipid (hub) of the BA9 “turquoise”/ hippocampus “blue” module was a Phosphatidylserine (PS(32:1)), increased in both AD donors and TREM2 carriers (AD-TREM2wtversus controls: beta=0.468, 95% CI 0.05 – 0.89, p= 3.02E-02; and AD-TREM2varversus controls: beta=1.00, 95% CI 0.53 – 1.47, p= 5.57E-03), whereas the strongest association was observed with a Ceramide (Cer(d38:1)) (AD-TREM2wtversus controls: beta=0.663, 95% CI 0.17 – 1.16, p= 8.9E-03; and AD-TREM2varversus controls: beta=1.31, 95% CI 0.78 – 1.84, p= 4.35E-06).The consistent increase in TREM2 ligands such as Ceramides and Phosphatidyl-serines in the brains of AD donors, particularly in carriers ofTREM2risk variants, could reflect the presence of AD-associated damage signals in the form of stressed/apoptotic cells and damaged myelin.
Publisher
Cold Spring Harbor Laboratory
Reference125 articles.
1. Prince M , Wimo A , Guerchet M , Ali G-C , Wu Y-T , Prina M . World Alzheimer Report 2015: The Global Impact of Dementia Prof Martin Prince, Prof Anders Wimo, Dr Maëlenn Guerchet, Miss Gemma-Claire Ali, Dr Yu-Tzu Wu and Dr Matthew Prina. 2015. 2015.
2. Pathways linking Alzheimer’s disease risk genes expressed highly in microglia
3. Jones L , Holmans PA , Hamshere ML , et al. Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer’s Disease. PLoS ONE. 2010;5(11)NOT IN FILE.
4. TREM2 Variants in Alzheimer's Disease
5. Variant ofTREM2Associated with the Risk of Alzheimer's Disease